Complete Medical Communications

Belkins
Complete Medical Communications provides world-class, tailored support for a wide range of medical publications & healthcare communications programs across many therapy areas.

Related News

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc | October 07, 2020

news image

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

Read More

A FAST-MOVING VIRUS PITS TREATING PATIENTS AGAINST FINDING A CURE

Bloomberg | April 05, 2020

news image

The frenzied hunt for drugs to ease Covid-19 could make it more difficult for scientists to find lasting treatments. Pharmaceutical-research experts are raising concerns that attempts to offer desperate coronavirus patients some form of treatment may hobble crucial studies of which drugs actually work and which ones don't. More than 100 off-the-shelf and experimental therapies are being tested either formally or informally for the coronavirus disease, including hydroxychloroquine, the antima...

Read More

PHARMACY MARKET

CASCADE CHEMISTRY INITIATES $14 MILLION EXPANSION OF CGMP PHARMACEUTICAL MANUFACTURING CAPACITY

Cascade Chemistry | February 19, 2021

news image

Cascade Chemistry, a main pharmaceutical contract development and manufacturing organization, today declared inception of development of new offices intended to expand the organization's ability to manufacture APIs (dynamic pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures). The new offices, expected to be operational in the main quarter of 2022, will eventually expand the organization's floor space just about three-overl...

Read More

PHARMA TECH

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

news image

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More

Moleculin Biotech, Inc | October 07, 2020

news image

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

Read More

Bloomberg | April 05, 2020

news image

A FAST-MOVING VIRUS PITS TREATING PATIENTS AGAINST FINDING A CURE

The frenzied hunt for drugs to ease Covid-19 could make it more difficult for scientists to find lasting treatments. Pharmaceutical-research experts are raising concerns that attempts to offer desperate coronavirus patients some form of treatment may hobble crucial studies of which drugs actually work and which ones don't. More than 100 off-the-shelf and experimental therapies are being tested either formally or informally for the coronavirus disease, including hydroxychloroquine, the antima...

Read More

PHARMACY MARKET

Cascade Chemistry | February 19, 2021

news image

CASCADE CHEMISTRY INITIATES $14 MILLION EXPANSION OF CGMP PHARMACEUTICAL MANUFACTURING CAPACITY

Cascade Chemistry, a main pharmaceutical contract development and manufacturing organization, today declared inception of development of new offices intended to expand the organization's ability to manufacture APIs (dynamic pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures). The new offices, expected to be operational in the main quarter of 2022, will eventually expand the organization's floor space just about three-overl...

Read More

PHARMA TECH

Quantum Leap, SignalPath | February 24, 2021

news image

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More